Loading company…
Star Therapeutics develops antibody therapies for rare diseases that share common biological pathways.
Founded in 2018 and based in California, US, Star Therapeutics develops antibody therapies for rare diseases with shared pathobiology. Its portfolio includes Electra Therapeutics, focused on immunological diseases and cancer, and Vega Therapeutics, focused on rare blood disorders. In September 2025, it raised USD 125 million in Series D funding co-led by Sanofi Ventures and Viking Global Investors, with new and returning investors participating, to support testing a monthly injection for inherited bleeding disorders.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in